Topic 13: | Germline BRCA mutation testing for patients with prostate cancer |
Topic 14: | Use of PARP inhibitors for patients with metastatic prostate cancer and a germline BRCA mutation |
FACULTY |
Emmanuel S Antonarakis, MD Associate Professor of Oncology and Urology Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland |
A Oliver Sartor, MD CE and Bernadine Laborde Professor for Cancer Research Medical Director, Tulane Cancer Center Assistant Dean for Oncology Tulane Medical School New Orleans, Louisiana |
Howard I Scher, MD D Wayne Calloway Chair in Urologic Oncology Co-Chair Center for Mechanism Based Therapy Head, Biomarker Development Initiative Member and Attending Physician Genitourinary Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York |
Matthew R Smith, MD, PhD Claire and John Bertucci Endowed Chair in Genitourinary Cancers Professor of Medicine Harvard Medical School Director Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Boston, Massachusetts |
Cora N Sternberg, MD Clinical Director Englander Institute for Precision Medicine Weill Cornell Medicine Hematology/Oncology New York, New York |
MODERATOR |
Neil Love, MD Research To Practice Miami, Florida |